GeneBioTech Co Ltd
KOSDAQ:086060
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GeneBioTech Co Ltd
Cash Equivalents
GeneBioTech Co Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GeneBioTech Co Ltd
KOSDAQ:086060
|
Cash Equivalents
₩10.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
Celltrion Inc
KRX:068270
|
Cash Equivalents
-₩300
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash Equivalents
₩10.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash Equivalents
₩66.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash Equivalents
₩112B
|
CAGR 3-Years
65%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
GeneBioTech Co Ltd
Glance View
Gene Bio Tech Co., Ltd. engages in the manufacture of fermented biomass. The company is headquartered in Gongju, Chungcheongnam-Do. The company went IPO on 2006-04-28. is a company mainly engaged in the production and sale of feed additives and animal drugs. Along with subsidiaries, the Company operates its business through two segments. The Additive segment is involved in the manufacturing and sale of fermented products and bio starches. The Animal Drug segment is involved in the manufacturing and sale of livestock and fish medicine. The main products include vitamins, minerals, antibiotics, nutrients, immune stimulators, digestion and absorption promoters, among others. The firm distributes its products within the domestic market and to overseas markets, including America.
See Also
What is GeneBioTech Co Ltd's Cash Equivalents?
Cash Equivalents
10.5B
KRW
Based on the financial report for Sep 30, 2025, GeneBioTech Co Ltd's Cash Equivalents amounts to 10.5B KRW.
What is GeneBioTech Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
4%
Over the last year, the Cash Equivalents growth was 0%. The average annual Cash Equivalents growth rates for GeneBioTech Co Ltd have been 2% over the past three years , 7% over the past five years , and 4% over the past ten years .
